Kyu-Ho Choi1, Ie Ryung Yoo2, Eun Ji Han1, Yeon Sil Kim3, Gi Won Kim3, Sae Jung Na1, Dong-Il Sun4, So Lyung Jung1, Chan-Kwon Jung5, Min-Sik Kim4, So-Yeon Lee1, Sung Hoon Kim1. 1. Department of Radiology, The Catholic University of Korea, Seoul, Korea. 2. Department of Radiology, The Catholic University of Korea, Seoul, Korea ; Department of Nuclear Medicine, Seoul St.Mary's Hospital, The Catholic University of Korea, Seochogu Banpodong 505, Seoul, Korea 137-701. 3. Department of Radiation Oncology, The Catholic University of Korea, Seoul, Korea. 4. Department of Otolaryngology-Head and Neck Surgery, The Catholic University of Korea, Seoul, Korea. 5. Department of Hospital Pathology, The Catholic University of Korea, Seoul, Korea.
Abstract
PURPOSE: We assessed the prognostic value of metabolic tumor volume (MTV) measured using(18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) inpatients with locally advanced head and neck squamous cell carcinoma (HNSCC). METHODS: We retrospectively reviewed 56 patients (51 men, five women; mean age 56.0 ± 8.8years) who had locally advanced HNSCC and underwent FDG PET/CT for initial evaluation. All patients had surgical resection and radiotherapy with or without concurrent chemotherapy. The peak standardized uptake value (SUVpeak) and MTV of the target lesion, including primary HNSCC andmetastatic cervical lymph nodes, were measured from FDG PET/CT images. We compared SUVpeak, MTV, and clinicopathologic variables such as age, Eastern Cooperative Oncology Group (ECOG) performance status, pN stage, pT stage, TNM stage, histologic grade and treatment modality to disease-free survival (DFS) and overall survival (OS). RESULTS: On the initial FDG PET/CT scans, the median SUVpeak was 7.8 (range, 1.8-19.0) and MTV was17.0 cm(3) (range, 0.1-131.0 cm(3)). The estimated 2-year DFS and OS rates were 67.2% and 81.8%. The cutoff points of SUVpeak 6.2 and MTV 20.7 cm(3) were the best discriminative values for predicting clinical outcome. MTV and ECOG performance status were significantly related to DFS and OS on univariate and multivariate analyses (p < 0.05). CONCLUSION: The MTV obtained from initial FDG PET/CT scan is a significant prognostic factor for disease recurrence and mortality in locally advanced HNSCC treated with surgery and radiotherapy with or without chemotherapy.
PURPOSE: We assessed the prognostic value of metabolic tumor volume (MTV) measured using(18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) inpatients with locally advanced head and neck squamous cell carcinoma (HNSCC). METHODS: We retrospectively reviewed 56 patients (51 men, five women; mean age 56.0 ± 8.8years) who had locally advanced HNSCC and underwent FDG PET/CT for initial evaluation. All patients had surgical resection and radiotherapy with or without concurrent chemotherapy. The peak standardized uptake value (SUVpeak) and MTV of the target lesion, including primary HNSCC andmetastatic cervical lymph nodes, were measured from FDG PET/CT images. We compared SUVpeak, MTV, and clinicopathologic variables such as age, Eastern Cooperative Oncology Group (ECOG) performance status, pN stage, pT stage, TNM stage, histologic grade and treatment modality to disease-free survival (DFS) and overall survival (OS). RESULTS: On the initial FDG PET/CT scans, the median SUVpeak was 7.8 (range, 1.8-19.0) and MTV was17.0 cm(3) (range, 0.1-131.0 cm(3)). The estimated 2-year DFS and OS rates were 67.2% and 81.8%. The cutoff points of SUVpeak 6.2 and MTV 20.7 cm(3) were the best discriminative values for predicting clinical outcome. MTV and ECOG performance status were significantly related to DFS and OS on univariate and multivariate analyses (p < 0.05). CONCLUSION: The MTV obtained from initial FDG PET/CT scan is a significant prognostic factor for disease recurrence and mortality in locally advanced HNSCC treated with surgery and radiotherapy with or without chemotherapy.
Entities:
Keywords:
FDG PET/CT; Head and neck squamous cell carcinoma; Metabolic tumor volume; Prognostic factor; Surgery
Authors: Vincent F H Chong; Jia-Yin Zhou; James B K Khoo; Kap-Luk Chan; Jing Huang Journal: Int J Radiat Oncol Biol Phys Date: 2005-11-03 Impact factor: 7.038
Authors: H Minn; M Lapela; P J Klemi; R Grénman; S Leskinen; P Lindholm; J Bergman; E Eronen; M Haaparanta; H Joensuu Journal: J Nucl Med Date: 1997-12 Impact factor: 10.057
Authors: Christophe Le Tourneau; Guy-Michel Jung; Christian Borel; Guy Bronner; Henri Flesch; Michel Velten Journal: Acta Otolaryngol Date: 2008-06 Impact factor: 1.494
Authors: Trang H La; Edith J Filion; Brit B Turnbull; Jackie N Chu; Percy Lee; Khoa Nguyen; Peter Maxim; Andy Quon; Edward E Graves; Billy W Loo; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-14 Impact factor: 7.038
Authors: Jang Yoo; Joon Young Choi; Kyu Taek Lee; Jin Seok Heo; Soo Bin Park; Seung Hwan Moon; Yearn Seong Choe; Kyung-Han Lee; Byung-Tae Kim Journal: Nucl Med Mol Imaging Date: 2012-06-19
Authors: Ho Seong Kim; Joon Young Choi; Dong Wook Choi; Ho Yeong Lim; Joo Hee Lee; Sun Pyo Hong; Young Seok Cho; Kyung-Han Lee; Byung-Tae Kim Journal: Nucl Med Mol Imaging Date: 2014-02-07